Novo Nordisk Insulin Product Discontinuations: Key Updates & Info
Novo Nordisk Insulin Product Discontinuation
Novo Nordisk has advised of a gradual discontinuation to the following insulin products over the next two years:
- LEVEMIR FLEXPEN insulin detemir (rys) 100 U/mL injection cartridge
- LEVEMIR PENFILL insulin detemir (rys) 100 U/mL injection cartridge
- PROTAPHANE INNOLET human insulin (rys) 100IU/mL injection multidose cartridge
- PROTAPHANE PENFILL human insulin (rys) 100IU/mL injection multidose cartridge
- FIASP FLEXTOUCH insulin aspart (rys) 100 units/mL solution for injection 3 mL pre-filled pen
- FIASP insulin aspart (rys) vial 100 units/mL solution for injection 10 mL
- ACTRAPID PENFILL human insulin (rys) 100IU/mL injection multidose cartridge
- RYZODEG 70/30 FLEXTOUCH 70% insulin degludec (rys) / 30% insulin aspart (rys) 100 U/mL cartridge
In some cases, while one presentation of a product may be discontinued, the product remains available in another form. For example, the FlexTouch prefilled pen may be replaced by the Penfill cartridge.
Novo Nordisk has indicated that they believe there will be a sufficient supply of Novopens to meet the anticipated increase in demand for Penfill presentations.
The Therapeutic Goods Administration (TGA) has prepared an information page on their website to assist health professionals and patients in managing these discontinuations. The page will be updated as the TGA receives new information and can be found here: Upcoming changes to the supply of some insulin products | Therapeutic Goods Administration (TGA).
